Heart failure & cardiomyopathies
Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices
Authors' conclusion
Apixaban demonstrated safe and favourable long-term outcomes in a cohort of HM3 LVAD patients over a mean follow-up of more than 2 years.
Study context
- Population
- HM3 LVAD patients transitioned from warfarin to apixaban (difficulty maintaining therapeutic international normalized ratio (INR)), May 2018–June 2022
- Participants
- 8 patients
- Exposure
- Apixaban vs warfarin
- Outcome
- Survival and thrombo-embolic events (LVAD pump thrombosis, stroke, arterial thrombo-embolic events, pump exchange)
- Follow-up
- Mean 789 days after transition to apixaban
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
mean 789 days after transition to apixaban
- Patients with LVAD pump thrombosis, stroke, arterial thrombo-embolic event, pump exchange or death
- 0
Observational data: associations, not effects.
Safety
| Outcome | Warfarin | Apixaban |
|---|---|---|
| Bleeding events | ||
| Patients with bleeding | 5 | — not stated in the abstract |
| Bleeding events | 8 | — not stated in the abstract |
| Major | 1 | — not stated in the abstract |
| Minor | 7 | — not stated in the abstract |
| Major GI bleed | — not stated in the abstract | 1 |
— not stated in the abstract
- Bleeding events: warfarin minor: five GI bleeds, one haematuria, one haemoptysis
- Bleeding events: apixaban: patient with angioectasia, requiring two packed red blood cells (pRBCs) and endoscopic clipping
Original publication
Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices. ESC Heart Fail. Published 9 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →